Abstract
Cancer immunotherapy with interleukin-2 (IL-2) has demonstrated long term disease control in metastatic renal cell carcinoma and malignant melanoma. With introduction of novel kinase inhibitors, immunomodulatory molecules, cytokines, and vaccines for treatment of cancer there is an increased interest in combining these therapeutic strategies with IL-2. Here we discuss toxicity and established activity of IL-2 in the management of advanced malignancies, and speculate on future use of this cytokine for treatment of cancer.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 3297-3302 |
| Number of pages | 6 |
| Journal | Current Medicinal Chemistry |
| Volume | 17 |
| Issue number | 29 |
| State | Published - Oct 21 2010 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- Immunotherapy
- Interleukin-2
- Kidney cancer
- Melanoma
Fingerprint
Dive into the research topics of 'Interleukin 2 in cancer therapy'. Together they form a unique fingerprint.Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS